Development of fixed dose combination tablets of aripiprazole plus divalproex sodium and their simultaneous determination using HPLC-UV

References

• Farooq S, Singh SP. Fixed dose-combination products in psychiatry: systematic review and meta-analysis. J Psychopharmacol (Oxford) 2014;29:556–64.
   PubMed Web of Science ®Google Scholar
• Sheen P-C, Conroy DF, Feld KM. Formulation studies of furosemide-amiloride HCI combination tablets. Drug Dev Ind Pharm 1996;22:1021–4.
   Web of Science ®Google Scholar
• Shelton RC. The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination. Ther Clin Risk Manag 2006;2:187–92.
   PubMedGoogle Scholar
• Ahmed Z, Subhan F, Shah MT, Farooq S. Effect of fasting on serum lithium levels: an experimental study in animal models. Pak J Pharm Sci 2014;27:33–7.
   PubMed Web of Science ®Google Scholar
• Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155:12–21.
   PubMed Web of Science ®Google Scholar
• Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164:549–50.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005;7:5–69.
   PubMed Web of Science ®Google Scholar
• Berk M, Dodd S, Berk L. The management of bipolar disorder in primary care: a review of existing and emerging therapies. Psychiatry Clin Neurosci 2005;59:229–39.
   PubMed Web of Science ®Google Scholar
• Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000;61:35–40.
   PubMed Web of Science ®Google Scholar
• Borovinskaya M, Robert B, Plakogiannis FM. Evaluation of in vitro percutaneous absorption of olanzapine and fluoxetine HCl: enhancement properties of olanzapine. Drug Dev Ind Pharm 2012;38:227–34.
   PubMed Web of Science ®Google Scholar
• Haridas R, Parkar S, Ghulam R, et al. Olanzapine and fluoxetine combination in severe or resistant depression. Indian J Psychiatry 2003;45:234
   PubMedGoogle Scholar
• Colom F, Vieta E, Tacchi M, et al. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord 2005;7: 24–31.
   PubMed Web of Science ®Google Scholar
• Perlis RH. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am J Manag Care 2007;13:S178–88.
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651–8.
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol (Oxford) 2006;20:536–46.
   PubMed Web of Science ®Google Scholar
• Vieta E, T’joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008;165: 1316–25.
   PubMed Web of Science ®Google Scholar
• Keck P, Orsulak P, Cutler A, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009;112:36–49.
   PubMed Web of Science ®Google Scholar
• Pae C-U, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008;22:367–88.
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480–91.
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626–37.
   PubMed Web of Science ®Google Scholar
• Fujisaki Y, Tsukune T, Funyû M, et al. Development of sustained-release tablets containing sodium valproate: in vitro and in vivo correlation. Drug Dev Ind Pharm 2006;32:207–17.
   PubMed Web of Science ®Google Scholar
• Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull 2002;37:5–16.
   Google Scholar
• Ardiana F, Lestari MLAD, Indrayanto G. Chapter Two – Aripiprazole. In: Harry GB, ed. Profiles of drug substances, excipients and related methodology. New York: Academic Press; 2013:35–85.
   Google Scholar
• Musenga A, Saracino MA, Spinelli D, et al. Analysis of the recent antipsychotic aripiprazole in human plasma by capillary electrophoresis and high-performance liquid chromatography with diode array detection. Anal Chim Acta 2008;612:204–11.
   PubMed Web of Science ®Google Scholar
• Kishore P, Rajani Kumar V, Satyanarayana V, Krishna D. HPLC determination of valproic acid in human serum. Die Pharmazie 2003;58:378–80.
   PubMed Web of Science ®Google Scholar
• Thakkar R, Saravaia H, Ambasana M, et al. An isocratic method for quantification of valproic acid and its related impurities using ion pair reagent by ultraperformance liquid chromatography. ISRN Chromatogr 2012;2012:1–5.
   Google Scholar
• Ravinder S, Bapuji AT, Mukkanti K, et al. Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. J Chromatogr Sci 2012;50:893–901.
   PubMed Web of Science ®Google Scholar
• Soponar F, Sandru M, David V. Quantitative evaluation of aripiprazole and its five related chemical impurities from pharmaceuticals using a HPLC-DAD method. Revue Roumaine Chimie 2014;59:1037–46.
   Web of Science ®Google Scholar
• Nikolic K, Filijović ND, Maričić B, Agbaba D. Development of a novel RP-HPLC method for the efficient separation of aripiprazole and its nine impurities. J Sep Sci 2013;36: 3165–75.
   PubMed Web of Science ®Google Scholar
• Sastry B, Gananadhamu S, Rao GD. RP-HPLC determination of aripiprazole in pharmaceutical formulations. Asian J Chem 2009;21:6643.
   Google Scholar
• Kirschbaum KM, Müller MJ, Zernig G, et al. Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin Chem 2005;51: 1718–21.
   PubMed Web of Science ®Google Scholar
• Marshall K, Lachman N, Liberman H, Kanig J. The theory and practice of industrial pharmacy. 3rd ed. Bombay: Varghese Publishing House; 1987:66–99.
   Google Scholar
• Vijayasankar G. Formulation development and evaluation of divalproex sodium extended release tablets. Int J Res Pharm Biomed Sci 2011;2:1–19.
   Google Scholar
• Chhater S, Rajesh K, Kshitij A, Nema R. Development and evaluation of enteric coated tablet containing diclofenac sodium. Int J Pharm Sci Nanotechnol 2009;2:443–9.
   Google Scholar
• United States Pharmacopeia and National Formulary (USP 37–NF 32). The United States Pharmacopeial Convention. Vol. 4. Rockville, MD; 2014;2671.
   Google Scholar
• Epshtein N. Validation of HPLC techniques for pharmaceutical analysis. Pharm Chem J 2004;38:212–28.
   Google Scholar
• ICH Guide. Q2B. Validation of analytical procedures: methodology. International Conference on Harmonization. International Conference on Harmonization Fed Reg (62 FR 2463). Geneva: FPMA; 1997.
   Google Scholar
• DiNunzio JC, Williams III, RO. CNS disorders-current treatment options and the prospects for advanced therapies. Drug Dev Ind Pharm 2008;34:1141–67.
   PubMed Web of Science ®Google Scholar
• Magiria S, Siamouli M, Gonda X, et al. Evidence based combination therapy for bipolar disorder. In: Ritsner MS, ed. Polypharmacy in Psychiatry Practice, VolumeII. Berlin: Springer; 2013:159–77.
   Google Scholar
• Haeberle A, Greil W, Russmann S, Grohmann R. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP . BMC Psychiatry 2012;12:153.
   PubMed Web of Science ®Google Scholar
• Kwon JS, Jang JH, Kang D-H, et al. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin Neurosci 2009;63:73–81.
   PubMed Web of Science ®Google Scholar
• Hanssens L, L'Italien G, Loze J-Y, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008;8:95.
   PubMed Web of Science ®Google Scholar